Skip to content

Efficacy Evaluation of Ultrasound-Guided Curved Wire Loop Transverse Carpal Ligament Release versus Conventional Open Transverse Carpal Ligament Release for Carpal Tunnel Syndrome: A Single-Center, Bidirectional Cohort Study

Efficacy Evaluation of Ultrasound-Guided Curved Wire Loop Transverse Carpal Ligament Release versus Conventional Open Transverse Carpal Ligament Release for Carpal Tunnel Syndrome: A Single-Center, Bidirectional Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095972
Enrollment
Unknown
Registered
2025-01-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal tunnel syndrome

Interventions

exposure group:ultrasound-guided curved wire loop transverse carpal ligament release
control group:Open Carpal Tunnel Release

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) 40 to 70 years of age; (2) Have typical symptoms of carpal tunnel syndrome (e.g., numbness, tingling, weakness, or pain in the fingers; symptoms aggravated by repetitive or sustained grasping; worsening of symptoms at night) and typical signs (impaired sensation or weakness in the hand; positive Tinel's sign or Phalen's test of the median nerve); (3) Symptoms consistent with typical or probable carpal tunnel syndrome according to the Katz hand chart diagnostic criteria for carpal tunnel syndrome; (4) Ultrasound suggesting thickening of the transverse carpal ligament and compression of the median nerve; (5) Conservative treatment (e.g., braking, oral NSAIDs medication, local corticosteroid injections, etc.) for more than 3 months with poor results; (6) Being able to understand the study process, voluntarily participating in this study, and being able to accept the 6-month postoperative follow-up; (7) Coagulation function tests are basically normal (based on the normal values in the laboratory of each study centre): a. Prolongation of plasma prothrombin time (PT) <=3s; b. Prolongation of activated partial thromboplastin time (APTT) <=10s.

Exclusion criteria

Exclusion criteria: (1) Ultrasonographic findings of a median nerve bifurcation or vestigial median artery at the entrance to the carpal tunnel, or compression at the carpal tunnel caused by a cyst, tumor, or fracture mass; (2) Systemic infection or localized infection at the surgical site; (3) Previous surgery for carpal tunnel syndrome on the affected side of the current procedure; (4) Patients with a combination of uncontrolled epilepsy, radicular cervical spondylosis, or diabetic peripheral neuropathy; (5) Allergy to local anesthetic drugs; (6) Inability to complete the questionnaire due to language or cognitive impairment; (7) Pregnant or lactating women; (8) Those with severe cardiac disease or discomfort that is not expected to tolerate the procedure, including, but not limited to: fatal arrhythmia or higher grade atrioventricular block, unstable angina pectoris, clinically significant cardiac valvulopathy, electrocardiogram showing transmural myocardial infarction, and uncontrolled hypertension; (9) Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study, has a concomitant disease or condition that may interfere with participation in the study, or has any serious medical disorder that may affect the safety of the subject (e.g., psychiatric disorders, uncontrolled cardiac disease, hypertension, active or uncontrolled infections, etc.).

Design outcomes

Primary

MeasureTime frame
Carpal tunnel syndrome symptoms are severe;Carpal tunnel syndrome functional status;

Secondary

MeasureTime frame
Total hospital expenses;length of stay;

Countries

China

Contacts

Public ContactLong Yi

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

longyi_9129@sina.com+86 182 7392 3391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026